GILD

Gilead Sciences, Inc.

64.35
USD
1.08%
64.35
USD
1.08%
57.19 74.12
52 weeks
52 weeks

Mkt Cap 80.68B

Shares Out 1.25B

Chat
Send me real-time posts from this site at my email

Gilead To Report Q4 Earnings: Is A Beat In The Cards?

Biotech major Gilead Sciences Inc. (GILD - Free Report) is slated to report fourth-quarter 2021 results on Feb 1, after market close. The company has an excellent track record, with earnings beating estimates in all of the last four quarters, the average beat being 15.7%. In the last reported quarter, the company beat expectations by 54.07%. Gilead Sciences, Inc. Price and EPS Surprise What Our Model Predicts Our proven model predicts an earnings beat for Gilead this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Earnings ESP: Earnings ESP for Gilead is +2.03%, as the Zacks Consensus Estimate is pegged at $1.50 and the Most Accurate Estimate is pegged at $1.53. Zacks Rank: The company currently carries a Zacks Rank #3. Factors at Play Gilead did not provide any guidance for the fourth quarter. It upped its product sales outlook for 2021 concurrent with the third-quarter results suggesting an increase in sales in the fourth quarter. A decline in HIV franchise sales due to the loss of exclusivity of Truvada and Atripla adversely impacted the top line in the third quarter. Sales from this franchise came in at $4.2 billion in the third quarter. The trend is likely to have continued in the fourth quarter as well. Flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic in all three quarters. The trend is expected to have continued in the final quarter. Strong growth in Biktarvy sales might have offset the overall decline in sales in the quarter. Descovy sales decreased in the previous quarter due to lower net price. A similar trend has most likely prevailed in the to-be-reported quarter.The Zacks Consensus Estimate for sales of Biktarvy and Descovy is pegged at $2.4 billion and $435 million, respectively. Disclaimer: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any ... more

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue